Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.40 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/15/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (STDAF) Key Developments

Stada-Arzneimittel Mulls Acquisitions

Stada-Arzneimittel AG (DB:SAZ) is seeking for acquisitions. Helmut Kraft, Chief Executive Officer of Stada-Arzneimittel said in full year 2014 Stada Arzneimittel AG earnings call, “It continues to allow us to make smaller bolt-on acquisitions with a focus on branded products once again and platforms being set up in the growth markets. And as you've seen through the slides the platforms are already there in each country. We just have to continue to supply them. So a steady flow of smaller product acquisitions preferably in the self-pay market, products in profitable, rapidly-growing niches is what we're aiming for. And products to round off our portfolio, a range expansion and different product categories, and, what we're really focusing on, the potential for products to be internationalized, or at least within a European setting, within our European subsidies.”

Stada-Arzneimittel Ag Reports Preliminary Group Earnings Results for the Year 2014; Provides Earnings guidance for 2015

Stada-Arzneimittel AG reported preliminary group earnings results for the year 2014. Group sales were €2,062.2 million against €2,003.9 million a year ago. Operating profit was €251.5 million against €202.1 million a year ago. Operating profit, adjusted was €306.3 million against €266.2 million a year ago. In 2014, reported operating profit decreased significantly by 24% to €188.5 million against €248.3 million a year ago, mainly due to impairments of goodwill in the market regions CIS/Eastern Europe as well as Asia/Pacific & MENA. EBITDA was €418.8 million against €382.6 million a year ago. EBITDA, adjusted was €431.9 million against €414.3 million a year ago. Net income was €64.6 million against €121.4 million a year ago. Net income, adjusted was €186.2 million against €160.6 million a year ago. Earnings per share were €1.07 against €2.04 a year ago. Earnings per share, adjusted were €3.08 against €2.70 a year ago. Cash flow from operating activities amounted to €223.8 million in the reporting year against €203.7 million a year ago. For the outlook for 2015, the Executive Board anticipates slight growth in Group sales adjusted for currency and portfolio effects. The Executive Board however expects a decreased earnings contribution from Russia due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation. Taking these developments into account and based on current currency relations, the Executive Board expects a substantial decrease in adjusted EBITDA and adjusted net income. The Executive Board expects the ratio of net debt excluding further acquisitions to adjusted EBITDA to be at a level of nearly 3 in 2015.

STADA AG Presents at HSBC's 13th Pan European Equity Conference, Apr-01-2015

STADA AG Presents at HSBC's 13th Pan European Equity Conference, Apr-01-2015 . Venue: HSBC France Offices, 109 Avenue des Champs-Elysees, Paris, France. Speakers: Alexander Groschke, Director IR, Scherwin Johannsen, Manager IR.

Stada-Arzneimittel Ag Provides Unaudited Preliminary Earnings Guidance for the Year 2014 and 2015; Provides Dividend Guidance for Fiscal 2014

Stada-Arzneimittel AG provided unaudited preliminary earnings guidance for the year 2014. Group sales is expected to have risen by 3% to €2,062.2 million; Reported EBITDA is expected to have increased by 9% to €418.8 million; adjusted EBITDA is anticipated to have increased by 4% to €431.9 million. Overall, there were one-time special effects in the expected amount of €128.6 million before or €121.6 million after taxes. They include impairments on goodwill in the expected amount of €54.0 million before and after taxes as well as on further intangible assets in the expected amount of €22.0 million before and €21.7 million after taxes as a result of the significantly changed interest rate and currency environment as well as ongoing higher risks in the market region CIS/Eastern Europe. In light of this, reported net income is expected to have decreased by 47% to €64.6 million; Adjusted net income is anticipated to have increased by 16% to €186.2 million. Reported earnings per share are anticipated to have decreased to €1.07; and Adjusted earnings per share are expected to have increased to €3.08. As of the balance sheet date, net debt is expected to amount to €1,327.5 million; Cash flow from operating activities is expected to have amounted to €223.8 million in financial year 2014; Free cash out flow is anticipated to have amounted to €38.2 million; Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals is expected to have amounted to €157.4 million. For the preliminary outlook for 2015, the Executive Board currently anticipates growth in Group sales adjusted for currency and portfolio effects. From today's perspective, the Executive Board however expects a decreased earnings contribution from Russia due to the recent developments of the Russian ruble and increased risks in connection with consumer mood and the general market situation. Taking these developments into account and based on current currency relations, the Executive Board expects from the current perspective a substantial decrease in adjusted EBITDA and adjusted net income. Due to the decreased net income reported, the STADA Executive Board recommends that the Supervisory Board propose to the next Annual General Meeting on June 3, 2015 an unchanged dividend of €0.66 per common share for financial year 2014 against €0.66 for the last year. The resulting total dividend payment of €40.0 million reflects a significantly higher distribution ratio than the previous year at approximately 62% of net income reported.

Stada-Arzneimittel AG to Report Fiscal Year 2014 Results on Mar 26, 2015

Stada-Arzneimittel AG announced that they will report fiscal year 2014 results on Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAF:US $36.40 USD 0.00

STDAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.115.10 CHF -4.70
Hospira Inc $87.46 USD -0.21
Merck KGaA €104.05 EUR -3.96
Medicines Co/The $29.08 USD -0.04
UCB SA €68.97 EUR -1.99
View Industry Companies
 

Industry Analysis

STDAF

Industry Average

Valuation STDAF Industry Range
Price/Earnings 28.0x
Price/Sales 0.9x
Price/Book 2.1x
Price/Cash Flow 27.8x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.